$BIOX

Bioceres (BIOX) reported a challenging fiscal year 2026 with an 18% revenue decline to $238M, driven by seed business reconfiguration and lower crop protection performance. Quarterly revenue was $55.9M, with crop nutrition revenue growing 36%. Adjusted EBITDA improved to $600K from a $9.6M loss, aided by a 19% reduction in SG&A expenses. The company faces litigation and debt restructuring challenges, with total financial debt at $225.9M. Management targets a 40% gross margin for fiscal 2027 and

Bioceres Crop Solutions reported Q4 2026 revenue of $55.9M, flat YoY, and a net loss of $0.50 per share, missing estimates. Adjusted EBITDA turned positive at $0.6M. Full-year revenue fell 18% to $238.3M. CEO Federico Trucco emphasized business simplification and profitability. BIOX stock closed at $0.43, down 1.68% post-earnings.

Agriculture Investment Group Corp. and Granosur Holding Limited have reduced their combined stake in Bioceres Crop Solutions Corp. (BIOX) to 9.05%, owning 5,776,807 ordinary shares. This reduction followed open-market sales of over 1 million shares between March 13 and March 20, 2026, at prices ranging from $0.36 to $0.53 per share. The amended Schedule 13D filing indicates these are secondary-market trades and the reporting persons currently have no plans for corporate actions.

Bioceres Crop (BIOX) delivered earnings and revenue surprises of -200.00% and -18.37%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.

Bioceres Crop (BIOX) delivered earnings and revenue surprises of 80% and 3.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?